Preview
Sign-in for full Details 
Sign-in free and Explore the Exciting World of BiomedExperts:
- Over 1.500.000 Profiles
- More than 1.800 Organizations worldwide
- State of the Art Network Visualizations
- Manage your own Profile
- Locate Experts in your Country/Region
- Locate Experts in your 1. and 2. Level Network
- Connect to Experts Worldwide
NetworkView
George Bosl
This is a preview profile on BiomedExperts - the first literature-based scientific social network. It brings the right researchers
together and allows them to collaborate online. Collexis and Dell provide the BiomedExperts network of +1.5 Million pre-calculated profiles
free of charge to researchers worldwide.
Research Profile (preview)
Disorders
Procedures
Chemicals & Drugs
Concepts & Ideas
Sign-in to see full Profile
Network (preview)
91
Motzer, Robert
73
Bajorin, Dean
46
Chaganti, Raju
35
Sheinfeld, Joel
29
Reuter, Victor
29
Herr, Harry
24
Mazumdar, Madhu
22
Houldsworth, Jane
20
Scher, Howard
18
Pfister, David
18
Murty, Vundavalli
17
Sogani, Pramod
15
Bacik, Jennifer
14
Shah, Jatin
13
Vlamis, V
Sign-in to see all Coauthors
Publications
Sign-in to see all Publications
Sign in free and see...
Visualized networks:
See your personal network in
sophisticated graphical views
GeoTargeted Searches:
Locate experts around the world
and connect with global collaborators
Research Profiles:
See the visualized research activity
of experts around the globe
Sign-in to see more
Geonetwork of George Bosl (preview)
Cities where this author has publications
Cities where co-authors of this author have publications
Sign-in to see more
All Publications
-
2009: Korkola James E; Houldsworth Jane; Bosl George J; Chaganti R S K
Molecular events in germ cell tumours: linking chromosome-12 gain, acquisition of pluripotency and response to cisplatin.
BJU international 2009;104(9 Pt B):1334-8.
-
2009: Korkola James E; Houldsworth Jane; Feldman Darren R; Olshen Adam B; Qin Li-Xuan; Patil Sujata; Reuter Victor E; Bosl George J; Chaganti R S K
Identification and validation of a gene expression signature that predicts outcome in adult men with germ cell tumors.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009;27(31):5240-7.
-
2009: Bosl George J
Testicular granulosa cell tumors: rare tumors need to be studied too.
Oncology (Williston Park, N.Y.) 2009;23(9):796.
-
2009: Gopalan Anuradha; Dhall Deepti; Olgac Semra; Fine Samson W; Korkola James E; Houldsworth Jane; Chaganti Raju S; Bosl George J; Reuter Victor E; Tickoo Satish K
Testicular mixed germ cell tumors: a morphological and immunohistochemical study using stem cell markers, OCT3/4, SOX2 and GDF3, with emphasis on morphologically difficult-to-classify areas.
Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc 2009;22(8):1066-74.
-
2008: Sharp David S; Carver Brett S; Eggener Scott E; Kondagunta G Varuni; Motzer Robert J; Bosl George J; Sheinfeld Joel
Clinical outcome and predictors of survival in late relapse of germ cell tumor.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008;26(34):5524-9.
-
2008: Jathavedam Ashwin; Feldman Darren R; Ishill Nicole; Turkula Stefan; Patil Sujata; Bosl George J; Motzer Robert J; Weinstock David M
Infectious complications from high-dose chemotherapy and autologous stem cell transplantation for metastatic germ cell tumors.
Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 2008;14(5):595-600.
-
2008: Feldman Darren R; Bosl George J; Sheinfeld Joel; Motzer Robert J
Medical treatment of advanced testicular cancer.
JAMA : the journal of the American Medical Association 2008;299(6):672-84.
-
2008: Dash Atreya; Carver Brett S; Stasi Jason; Bajorin Dean F; Motzer Robert J; Bosl George J; Sheinfeld Joel
The indication for postchemotherapy lymph node dissection in clinical stage IS nonseminomatous germ cell tumor.
Cancer 2008;112(4):800-5.
-
2008: Korkola J E; Heck S; Olshen A B; Reuter V E; Bosl G J; Houldsworth J; Chaganti R S K
In vivo differentiation and genomic evolution in adult male germ cell tumors.
Genes, chromosomes & cancer 2008;47(1):43-55.
-
2008: Feldman Darren R; Bosl George J
Treatment of stage I seminoma: is it time to change your practice?
Journal of hematology & oncology 2008;1():22.
-
2007: Stephenson Andrew J; Bosl George J; Motzer Robert J; Bajorin Dean F; Stasi Jason P; Sheinfeld Joel
Nonrandomized comparison of primary chemotherapy and retroperitoneal lymph node dissection for clinical stage IIA and IIB nonseminomatous germ cell testicular cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007;25(35):5597-602.
-
2007: Carver Brett S; Serio Angel M; Bajorin Dean; Motzer Robert J; Stasi Jason; Bosl George J; Vickers Andrew J; Sheinfeld Joel
Improved clinical outcome in recent years for men with metastatic nonseminomatous germ cell tumors.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007;25(35):5603-8.
-
2007: Carver Brett S; Shayegan Bobby; Eggener Scott; Stasi Jason; Motzer Robert J; Bosl George J; Sheinfeld Joel
Incidence of metastatic nonseminomatous germ cell tumor outside the boundaries of a modified postchemotherapy retroperitoneal lymph node dissection.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007;25(28):4365-9.
-
2007: Feldman Darren R; Kondagunta G Varuni; Ginsberg Michelle S; Ishill Nicole; Patil Sujata; Cestaro John; Obbens Eugenie; Sheinfeld Joel; Bosl George J; Motzer Robert J
Phase II trial of ixabepilone in patients with cisplatin-refractory germ cell tumors.
Investigational new drugs 2007;25(5):487-90.
-
2007: Feldman Darren R; Bosl George J
Curing germ cell tumors after failure of high-dose chemotherapy: progress through clinical trials.
Nature clinical practice. Oncology 2007;4(9):508-9.
-
2007: Shayegan Bobby; Carver Brett S; Stasi Jason; Motzer Robert J; Bosl George J; Sheinfeld Joel
Clinical outcome following post-chemotherapy retroperitoneal lymph node dissection in men with intermediate- and poor-risk nonseminomatous germ cell tumour.
BJU international 2007;99(5):993-7.
-
2007: Eggener Scott E; Carver Brett S; Sharp David S; Motzer Robert J; Bosl George J; Sheinfeld Joel
Incidence of disease outside modified retroperitoneal lymph node dissection templates in clinical stage I or IIA nonseminomatous germ cell testicular cancer.
The Journal of urology 2007;177(3):937-42; discussion 942-3.
-
2007: Carver Brett S; Shayegan Bobby; Serio Angel; Motzer Robert J; Bosl George J; Sheinfeld Joel
Long-term clinical outcome after postchemotherapy retroperitoneal lymph node dissection in men with residual teratoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007;25(9):1033-7.
-
2007: Chadalavada Rajendrakumar S V; Korkola James E; Houldsworth Jane; Olshen Adam B; Bosl George J; Studer Lorenz; Chaganti R S K
Constitutive gene expression predisposes morphogen-mediated cell fate responses of NT2/D1 and 27X-1 human embryonal carcinoma cells.
Stem cells (Dayton, Ohio) 2007;25(3):771-8.
-
2007: Eggener Scott E; Carver Brett S; Loeb Stacy; Kondagunta G Varuni; Bosl George J; Sheinfeld Joel
Pathologic findings and clinical outcome of patients undergoing retroperitoneal lymph node dissection after multiple chemotherapy regimens for metastatic testicular germ cell tumors.
Cancer 2007;109(3):528-35.
-
2007: Motzer Robert J; Nichols Craig J; Margolin Kim A; Bacik Jennifer; Richardson Paul G; Vogelzang Nicholas J; Bajorin Dean F; Lara Primo N; Einhorn Lawrence; Mazumdar Madhu; Bosl George J
Phase III randomized trial of conventional-dose chemotherapy with or without high-dose chemotherapy and autologous hematopoietic stem-cell rescue as first-line treatment for patients with poor-prognosis metastatic germ cell tumors.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007;25(3):247-56.
-
2007: Kondagunta G Varuni; Bacik Jennifer; Sheinfeld Joel; Bajorin Dean; Bains Manjit; Reich Lillian; Deluca John; Budnick Amy; Ishill Nicole; Mazumdar Madhu; Bosl George J; Motzer Robert J
Paclitaxel plus Ifosfamide followed by high-dose carboplatin plus etoposide in previously treated germ cell tumors.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007;25(1):85-90.
-
2006: Houldsworth Jane; Korkola James E; Bosl George J; Chaganti R S K
Biology and genetics of adult male germ cell tumors.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2006;24(35):5512-8.
-
2006: Bajorin Dean F; Motzer Robert J; Bosl George J
Advances in urologic oncology: results progress from successful interdisciplinary research.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2006;24(35):5479-81.
-
2006: Carver Brett S; Bianco Fernando J; Shayegan Bobby; Vickers Andrew; Motzer Robert J; Bosl George J; Sheinfeld Joel
Predicting teratoma in the retroperitoneum in men undergoing post-chemotherapy retroperitoneal lymph node dissection.
The Journal of urology 2006;176(1):100-3; discussion 103-4.
-
2006: Su Yungpo Bernard; Vickers Andrew J; Zelefsky Michael J; Kraus Dennis H; Shaha Ashok R; Shah Jatin P; Serio Angel M; Harrison Louis B; Bosl George J; Pfister David G
Double-blind, placebo-controlled, randomized trial of granulocyte-colony stimulating factor during postoperative radiotherapy for squamous head and neck cancer.
Cancer journal (Sudbury, Mass.) 2006;12(3):182-8.
-
2006: Korkola James E; Houldsworth Jane; Chadalavada Rajendrakumar S V; Olshen Adam B; Dobrzynski Debbie; Reuter Victor E; Bosl George J; Chaganti R S K
Down-regulation of stem cell genes, including those in a 200-kb gene cluster at 12p13.31, is associated with in vivo differentiation of human male germ cell tumors.
Cancer research 2006;66(2):820-7.
-
2005: Kondagunta G Varuni; Bacik Jennifer; Bajorin Dean; Dobrzynski Deborah; Sheinfeld Joel; Motzer Robert J; Bosl George J
Etoposide and cisplatin chemotherapy for metastatic good-risk germ cell tumors.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(36):9290-4.
-
2005: Loehrer Patrick J; Bosl George J
Carboplatin for stage I seminoma and the sword of Damocles.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(34):8566-9.
-
2005: Ronnen Ellen A; Kondagunta G Varuni; Bacik Jennifer; Marion Stephanie; Bajorin Dean F; Sheinfeld Joel; Bosl George J; Motzer Robert J
Incidence of late-relapse germ cell tumor and outcome to salvage chemotherapy.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(28):6999-7004.
-
2005: Kondagunta G Varuni; Bacik Jennifer; Donadio Alessia; Bajorin Dean; Marion Stephanie; Sheinfeld Joel; Bosl George J; Motzer Robert J
Combination of paclitaxel, ifosfamide, and cisplatin is an effective second-line therapy for patients with relapsed testicular germ cell tumors.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(27):6549-55.
-
2005: Stephenson Andrew J; Bosl George J; Bajorin Dean F; Stasi Jason; Motzer Robert J; Sheinfeld Joel
Retroperitoneal lymph node dissection in patients with low stage testicular cancer with embryonal carcinoma predominance and/or lymphovascular invasion.
The Journal of urology 2005;174(2):557-60; discussion 560.
-
2005: Korkola James E; Houldsworth Jane; Dobrzynski Debbie; Olshen Adam B; Reuter Victor E; Bosl George J; Chaganti R S K
Gene expression-based classification of nonseminomatous male germ cell tumors.
Oncogene 2005;24(32):5101-7.
-
2005: Stephenson Andrew J; Bosl George J; Motzer Robert J; Kattan Michael W; Stasi Jason; Bajorin Dean F; Sheinfeld Joel
Retroperitoneal lymph node dissection for nonseminomatous germ cell testicular cancer: impact of patient selection factors on outcome.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(12):2781-8.
-
2005: Chadalavada Rajendrakumar S V; Houldsworth Jane; Olshen Adam B; Bosl George J; Studer Lorenz; Chaganti R S K
Transcriptional program of bone morphogenetic protein-2-induced epithelial and smooth muscle differentiation of pluripotent human embryonal carcinoma cells.
Functional & integrative genomics 2005;5(2):59-69.
-
2004: Koul Sanjay; McKiernan James M; Narayan Gopeshwar; Houldsworth Jane; Bacik Jennifer; Dobrzynski Deborah L; Assaad Adel M; Mansukhani Mahesh; Reuter Victor E; Bosl George J; Chaganti Raju S K; Murty Vundavalli V V S
Role of promoter hypermethylation in Cisplatin treatment response of male germ cell tumors.
Molecular cancer 2004;3():16.
-
2004: Varuni Kondagunta G; Bacik Jennifer; Schwartz Lawrence; Sheinfeld Joel; Bajorin Dean; Vuky Jacqueline; Marion Stephanie; Mazumdar Madhu; Bosl George J; Motzer Robert J
Phase II trial of temozolomide in patients with cisplatin-refractory germ cell tumors.
Investigational new drugs 2004;22(2):177-9.
-
2004: Kondagunta G Varuni; Sheinfeld Joel; Mazumdar Madhu; Mariani Tania V; Bajorin Dean; Bacik Jennifer; Bosl George J; Motzer Robert J
Relapse-free and overall survival in patients with pathologic stage II nonseminomatous germ cell cancer treated with etoposide and cisplatin adjuvant chemotherapy.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2004;22(3):464-7.
-
2003: Rabbani Farhang; Farivar-Mohseni Hesam; Leon Antonio; Motzer Robert J; Bosl George J; Sheinfeld Joel
Clinical outcome after retroperitoneal lymphadenectomy of patients with pure testicular teratoma.
Urology 2003;62(6):1092-6.
-
2003: Donadio Alessia C; Motzer Robert J; Bajorin Dean F; Kantoff Philip W; Sheinfeld Joel; Houldsworth Jane; Chaganti Raju S K; Bosl George J
Chemotherapy for teratoma with malignant transformation.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003;21(23):4285-91.
-
2003: McKiernan James M; Motzer Robert J; Bajorin Dean F; Bacik Jennifer; Bosl George J; Sheinfeld Joel
Reoperative retroperitoneal surgery for nonseminomatous germ cell tumor: clinical presentation, patterns of recurrence, and outcome.
Urology 2003;62(4):732-6.
-
2003: Sheinfeld Joel; Motzer Robert J; Rabbani Farhang; McKiernan James; Bajorin Dean; Bosl George J
Incidence and clinical outcome of patients with teratoma in the retroperitoneum following primary retroperitoneal lymph node dissection for clinical stages I and IIA nonseminomatous germ cell tumors.
The Journal of urology 2003;170(4 Pt 1):1159-62.
-
2003: Pohar Kamal S; Rabbani Farhang; Bosl George J; Motzer Robert J; Bajorin Dean; Sheinfeld Joel
Results of retroperitoneal lymph node dissection for clinical stage I and II pure embryonal carcinoma of the testis.
The Journal of urology 2003;170(4 Pt 1):1155-8.
-
2003: Mazumdar Madhu; Bacik Jennifer; Tickoo Satish K; Dobrzynski Deborah; Donadio Alessia; Bajorin Dean; Motzer Robert; Reuter Victor; Bosl George J
Cluster analysis of p53 and Ki67 expression, apoptosis, alpha-fetoprotein, and human chorionic gonadotrophin indicates a favorable prognostic subgroup within the embryonal carcinoma germ cell tumor.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003;21(14):2679-88.
-
2002: Koul Sanjay; Houldsworth Jane; Mansukhani Mahesh M; Donadio Alessia; McKiernan James M; Reuter Victor E; Bosl George J; Chaganti Raju S; Murty Vundavalli V
Characteristic promoter hypermethylation signatures in male germ cell tumors.
Molecular cancer 2002;1():8.
-
2002: Donadio Alessia C; Bosl George J
The future of therapy for nonseminomatous germ cell tumors.
Chest surgery clinics of North America 2002;12(4):769-89.
-
2002: Bourdon Véronique; Naef Félix; Rao Pulivarthi H; Reuter Victor; Mok Samuel C; Bosl George J; Koul Sanjay; Murty Vundaralli V V S; Kucherlapati Raju S; Chaganti R S K
Genomic and expression analysis of the 12p11-p12 amplicon using EST arrays identifies two novel amplified and overexpressed genes.
Cancer research 2002;62(21):6218-23.
-
2002: Singh Bhuvanesh; Stoffel Archontoula; Gogineni Swarna; Poluri Ashok; Pfister David G; Shaha Ashok R; Pathak Alok; Bosl George; Cordon-Cardo Carlos; Shah Jatin P; Rao Pulivarthi H
Amplification of the 3q26.3 locus is associated with progression to invasive cancer and is a negative prognostic factor in head and neck squamous cell carcinomas.
The American journal of pathology 2002;161(2):365-71.
-
2002: Osman Iman; Sherman Eric; Singh Bhuvanesh; Venkatraman Ennapadam; Zelefsky Michael; Bosl George; Scher Howard; Shah Jatin; Shaha Ashok; Kraus Dennis; Cordon-Cardo Carlos; Pfister David G
Alteration of p53 pathway in squamous cell carcinoma of the head and neck: impact on treatment outcome in patients treated with larynx preservation intent.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2002;20(13):2980-7.
-
2002: Houldsworth Jane; Heath Simon C; Bosl George J; Studer Lorenz; Chaganti R S K
Expression profiling of lineage differentiation in pluripotential human embryonal carcinoma cells.
Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research 2002;13(6):257-64.
-
2002: Tickoo Satish K; Hutchinson Brian; Bacik Jennifer; Mazumdar Madhu; Motzer Robert J; Bajorin Dean F; Bosl George J; Reuter Victor E
Testicular seminoma: a clinicopathologic and immunohistochemical study of 105 cases with special reference to seminomas with atypical features.
International journal of surgical pathology 2002;10(1):23-32.
-
2002: Vuky Jacqueline; Tickoo Satish K; Sheinfeld Joel; Bacik Jennifer; Amsterdam Alison; Mazumdar Madhu; Reuter Victor; Bajorin Dean F; Bosl George J; Motzer Robert J
Salvage chemotherapy for patients with advanced pure seminoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2002;20(1):297-301.
-
2001: Albanese J M; Reuter V E; Bosl G J; Houldsworth J; Chaganti R S
Expression of ID genes in differentiated elements of human male germ cell tumors.
Diagnostic molecular pathology : the American journal of surgical pathology, part B 2001;10(4):248-54.
-
2001: Dellit T H; Armas-Loughran B; Bosl G J; Sepkowitz K A; Thaler H; Blaskovich J
A method for assessing house staff workload as a function of length of stay.
JAMA : the journal of the American Medical Association 2001;286(9):1023-4.
-
2001: Mazumdar M; Bajorin D F; Bacik J; Higgins G; Motzer R J; Bosl G J
Predicting outcome to chemotherapy in patients with germ cell tumors: the value of the rate of decline of human chorionic gonadotrophin and alpha-fetoprotein during therapy.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2001;19(9):2534-41.
-
2001: Rabbani F; Sheinfeld J; Farivar-Mohseni H; Leon A; Rentzepis M J; Reuter V E; Herr H W; McCaffrey J A; Motzer R J; Bajorin D F; Bosl G J
Low-volume nodal metastases detected at retroperitoneal lymphadenectomy for testicular cancer: pattern and prognostic factors for relapse.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2001;19(7):2020-5.
-
2001: Houldsworth J; Reuter V E; Bosl G J; Chaganti R S
ID gene expression varies with lineage during differentiation of pluripotential male germ cell tumor cell lines.
Cell and tissue research 2001;303(3):371-9.
-
2001: Vuky J; Bains M; Bacik J; Higgins G; Bajorin D F; Mazumdar M; Bosl G J; Motzer R J
Role of postchemotherapy adjunctive surgery in the management of patients with nonseminoma arising from the mediastinum.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2001;19(3):682-8.
-
2000: Vuky J; McCaffrey J; Ginsberg M; Mariani T; Bajorin D F; Bosl G J; Motzer R J
Phase II trial of pyrazoloacridine in patients with cisplatin-refractory germ cell tumors.
Investigational new drugs 2000;18(3):265-7.
-
2000: Motzer R J; Sheinfeld J; Mazumdar M; Bains M; Mariani T; Bacik J; Bajorin D; Bosl G J
Paclitaxel, ifosfamide, and cisplatin second-line therapy for patients with relapsed testicular germ cell cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2000;18(12):2413-8.
-
2000: Motzer R J; Mazumdar M; Sheinfeld J; Bajorin D F; Macapinlac H A; Bains M; Reich L; Flombaum C; Mariani T; Tong W P; Bosl G J
Sequential dose-intensive paclitaxel, ifosfamide, carboplatin, and etoposide salvage therapy for germ cell tumor patients.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2000;18(6):1173-80.
-
2000: Morris M J; Bosl G J
Recognizing abnormal marker results that do not reflect disease in patients with germ cell tumors.
The Journal of urology 2000;163(3):796-801.
-
1999: Morris M J; Bosl G J
High-dose chemotherapy as primary treatment for poor-risk germ-cell tumors: the Memorial Sloan-Kettering experience (1988-1999).
International journal of cancer. Journal international du cancer 1999;83(6):834-8.
-
1999: Bosl G J
Germ cell tumor clinical trials in North America.
Seminars in surgical oncology 1999;17(4):257-62.
-
1999: Albanell J; Bosl G J; Reuter V E; Engelhardt M; Franco S; Moore M A; Dmitrovsky E
Telomerase activity in germ cell cancers and mature teratomas.
Journal of the National Cancer Institute 1999;91(15):1321-6.
-
1999: Murty V V; Montgomery K; Dutta S; Bala S; Renault B; Bosl G J; Kucherlapati R; Chaganti R S
A 3-Mb high-resolution BAC/PAC contig of 12q22 encompassing the 830-kb consensus minimal deletion in male germ cell tumors.
Genome research 1999;9(7):662-71.
-
1999: Feuer E J; Sheinfeld J; Bosl G J
Does size matter? Association between number of patients treated and patient outcome in metastatic testicular cancer.
Journal of the National Cancer Institute 1999;91(10):816-8.
-
1998: Liu D; Abolhoda A; Burt M E; Martini N; Bains M S; Downey R J; Rusch V W; Bosl G J; Ginsberg R J
Pulmonary metastasectomy for testicular germ cell tumors: a 28-year experience.
The Annals of thoracic surgery 1998;66(5):1709-14.
-
1998: Rao P H; Houldsworth J; Palanisamy N; Murty V V; Reuter V E; Motzer R J; Bosl G J; Chaganti R S
Chromosomal amplification is associated with cisplatin resistance of human male germ cell tumors.
Cancer research 1998;58(19):4260-3.
-
1998: Harrison L B; Raben A; Pfister D G; Zelefsky M; Strong E; Shah J P; Spiro R H; Shaha A; Kraus D H; Schantz S P; Carper E; Bodansky B; White C; Bosl G
A prospective phase II trial of concomitant chemotherapy and radiotherapy with delayed accelerated fractionation in unresectable tumors of the head and neck.
Head & neck 1998;20(6):497-503.
-
1998: Maerz W J; Baselga J; Reuter V E; Mellado B; Myers M L; Bosl G J; Spinella M J; Dmitrovsky E
FGF4 dissociates anti-tumorigenic from differentiation signals of retinoic acid in human embryonal carcinomas.
Oncogene 1998;17(6):761-7.
-
1998: Houldsworth J; Xiao H; Murty V V; Chen W; Ray B; Reuter V E; Bosl G J; Chaganti R S
Human male germ cell tumor resistance to cisplatin is linked to TP53 gene mutation.
Oncogene 1998;16(18):2345-9.
-
1998: Bosl G J
Germ cell tumors: there is still plenty to learn.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1998;16(4):1244-7.
-
1998: Sogani P C; Perrotti M; Herr H W; Fair W R; Thaler H T; Bosl G
Clinical stage I testis cancer: long-term outcome of patients on surveillance.
The Journal of urology 1998;159(3):855-8.
-
1998: Bajorin D F; Mazumdar M; Meyers M; Motzer R J; Vlamis V; Lin P; Bosl G J
Metastatic germ cell tumors: modeling for response to chemotherapy.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1998;16(2):707-15.
-
1998: Motzer R J; Amsterdam A; Prieto V; Sheinfeld J; Murty V V; Mazumdar M; Bosl G J; Chaganti R S; Reuter V E
Teratoma with malignant transformation: diverse malignant histologies arising in men with germ cell tumors.
The Journal of urology 1998;159(1):133-8.
-
1997: Bosl G J; Malbin K F
Implementation of practice guidelines.
Oncology (Williston Park, N.Y.) 1997;11(11A):33-8.
-
1997: McCaffrey J A; Bajorin D F; Scher H I; Bosl G J
Combined-modality therapy for bladder cancer.
Oncology (Williston Park, N.Y.) 1997;11(9 Suppl 9):18-26.
-
1997: Afifi H Y; Bosl G J; Burt M E
Mediastinal growing teratoma syndrome.
The Annals of thoracic surgery 1997;64(2):359-62.
-
1997: Bosl G J; Motzer R J
Testicular germ-cell cancer.
The New England journal of medicine 1997;337(4):242-53.
-
1997: McCaffrey J A; Mazumdar M; Bajorin D F; Bosl G J; Vlamis V; Motzer R J
Ifosfamide- and cisplatin-containing chemotherapy as first-line salvage therapy in germ cell tumors: response and survival.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1997;15(7):2559-63.
-
1997: Xiao H; Mazumdar M; Bajorin D F; Sarosdy M; Vlamis V; Spicer J; Ferrara J; Bosl G J; Motzer R J
Long-term follow-up of patients with good-risk germ cell tumors treated with etoposide and cisplatin.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1997;15(7):2553-8.
-
1997: Motzer R J; Mazumdar M; Bajorin D F; Bosl G J; Lyn P; Vlamis V
High-dose carboplatin, etoposide, and cyclophosphamide with autologous bone marrow transplantation in first-line therapy for patients with poor-risk germ cell tumors.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1997;15(7):2546-52.
-
1997: Bajorin D F; Bosl G J
Bleomycin in germ cell tumor therapy: not all regimens are created equal.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1997;15(5):1717-9.
-
1997: Herr H W; Sheinfeld J; Puc H S; Heelan R; Bajorin D F; Mencel P; Bosl G J; Motzer R J
Surgery for a post-chemotherapy residual mass in seminoma.
The Journal of urology 1997;157(3):860-2.
-
1997: Houldsworth J; Reuter V; Bosl G J; Chaganti R S
Aberrant expression of cyclin D2 is an early event in human male germ cell tumorigenesis.
Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research 1997;8(3):293-9.
-
1997: Bajorin D F; Motzer R J; Bosl G J
Germ cell tumors.
Current therapy in endocrinology and metabolism 1997;6():387-92.
-
1996: Bosl G J
Development and implementation of clinical management guidelines.
Oncology (Williston Park, N.Y.) 1996;10(11 Suppl):247-53.
-
1996: Zelefsky M J; Kraus D H; Pfister D G; Raben A; Shah J P; Strong E W; Spiro R H; Bosl G J; Harrison L B
Combined chemotherapy and radiotherapy versus surgery and postoperative radiotherapy for advanced hypopharyngeal cancer.
Head & neck 1996;18(5):405-11.
-
1996: Murty V V; Renault B; Falk C T; Bosl G J; Kucherlapati R; Chaganti R S
Physical mapping of a commonly deleted region, the site of a candidate tumor suppressor gene, at 12q22 in human male germ cell tumors.
Genomics 1996;35(3):562-70.
-
1996: Murty V V; Reuter V E; Bosl G J; Chaganti R S
Deletion mapping identifies loss of heterozygosity at 5p15.1-15.2, 5q11 and 5q34-35 in human male germ cell tumors.
Oncogene 1996;12(12):2719-23.
-
1996: Brenner P C; Herr H W; Morse M J; Sheinfeld J; Aprikian A; Bosl G J; Motzer R J; Bajorin D F; Schantz S; Fair W R; Burt M
Simultaneous retroperitoneal, thoracic, and cervical resection of postchemotherapy residual masses in patients with metastatic nonseminomatous germ cell tumors of the testis.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1996;14(6):1765-9.
-
1996: Motzer R J; Mazumdar M; Bosl G J; Bajorin D F; Amsterdam A; Vlamis V
High-dose carboplatin, etoposide, and cyclophosphamide for patients with refractory germ cell tumors: treatment results and prognostic factors for survival and toxicity.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1996;14(4):1098-105.
-
1996: Puc H S; Heelan R; Mazumdar M; Herr H; Scheinfeld J; Vlamis V; Bajorin D F; Bosl G J; Mencel P; Motzer R J
Management of residual mass in advanced seminoma: results and recommendations from the Memorial Sloan-Kettering Cancer Center.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1996;14(2):454-60.
-
1995: Kraus D H; Pfister D G; Harrison L B; Spiro R H; Strong E W; Zelefsky M; Bosl G J; Shah J P
Salvage laryngectomy for unsuccessful larynx preservation therapy.
The Annals of otology, rhinology, and laryngology 1995;104(12):936-41.
-
1995: Motzer R J; Sheinfeld J; Mazumdar M; Bajorin D F; Bosl G J; Herr H; Lyn P; Vlamis V
Etoposide and cisplatin adjuvant therapy for patients with pathologic stage II germ cell tumors.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1995;13(11):2700-4.
-
1995: Chaganti R S; Bosl G J
Germ cell tumors: unraveling a biological paradox.
Laboratory investigation; a journal of technical methods and pathology 1995;73(5):593-5.
-
1995: Moasser M M; Motzer R J; Khoo K S; Lyn P; Murphy B A; Bosl G J; Dmitrovsky E
all-trans retinoic acid for treating germ cell tumors. In vitro activity and results of a phase II trial.
Cancer 1995;76(4):680-6.
-
1995: Motzer R J; Chou T C; Schwartz L; Bosl G J; Bajorin D F; Hutter H
Paclitaxel in germ cell cancer.
Seminars in oncology 1995;22(3 Suppl 6):12-5.
-
1995: Bajorin D F; Nichols C R; Schmoll H J; Kantoff P W; Bokemeyer C; Demetri G D; Einhorn L H; Bosl G J
Recombinant human granulocyte-macrophage colony-stimulating factor as an adjunct to conventional-dose ifosfamide-based chemotherapy for patients with advanced or relapsed germ cell tumors: a randomized trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1995;13(1):79-86.
-
1995: Motzer R J; Rodriguez E; Reuter V E; Bosl G J; Mazumdar M; Chaganti R S
Molecular and cytogenetic studies in the diagnosis of patients with poorly differentiated carcinomas of unknown primary site.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1995;13(1):274-82.
-
1995: Puc H S; Bajorin D F; Bosl G J; Amsterdam A; Motzer R J
Phase II trial of topotecan in patients with cisplatin-refractory germ cell tumors.
Investigational new drugs 1995;13(2):163-5.
-
1994: Mathew S; Murty V V; Bosl G J; Chaganti R S
Loss of heterozygosity identifies multiple sites of allelic deletions on chromosome 1 in human male germ cell tumors.
Cancer research 1994;54(23):6265-9.
-
1994: Law T M; Motzer R J; Bajorin D F; Bosl G J
The management of patients with advanced germ cell tumors. Seminoma and nonseminoma.
The Urologic clinics of North America 1994;21(4):773-83.
-
1994: Murty V V; Li R G; Houldsworth J; Bronson D L; Reuter V E; Bosl G J; Chaganti R S
Frequent allelic deletions and loss of expression characterize the DCC gene in male germ cell tumors.
Oncogene 1994;9(11):3227-31.
-
1994: Motzer R J; Bajorin D F; Schwartz L H; Hutter H S; Bosl G J; Scher H I; Lyn P; Fischer P
Phase II trial of paclitaxel shows antitumor activity in patients with previously treated germ cell tumors.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1994;12(11):2277-83.
-
1994: Bosl G J; Bajorin D F
Etoposide plus carboplatin or cisplatin in good-risk patients with germ cell tumors: a randomized comparison.
Seminars in oncology 1994;21(5 Suppl 12):61-4.
-
1994: Chou T C; Motzer R J; Tong Y; Bosl G J
Computerized quantitation of synergism and antagonism of taxol, topotecan, and cisplatin against human teratocarcinoma cell growth: a rational approach to clinical protocol design.
Journal of the National Cancer Institute 1994;86(20):1517-24.
-
1994: Aprikian A G; Herr H W; Bajorin D F; Bosl G J
Resection of postchemotherapy residual masses and limited retroperitoneal lymphadenectomy in patients with metastatic testicular nonseminomatous germ cell tumors.
Cancer 1994;74(4):1329-34.
-
1994: Murty V V; Li R G; Mathew S; Reuter V E; Bronson D L; Bosl G J; Chaganti R S
Replication error-type genetic instability at 1q42-43 in human male germ cell tumors.
Cancer research 1994;54(15):3983-5.
-
1994: Murty V V; Bosl G J; Houldsworth J; Meyers M; Mukherjee A B; Reuter V; Chaganti R S
Allelic loss and somatic differentiation in human male germ cell tumors.
Oncogene 1994;9(8):2245-51.
-
1994: Schultz P K; Herr H W; Zhang Z F; Bajorin D F; Seidman A; Sarkis A; Fair W R; Scherr D; Bosl G J; Scher H I
Neoadjuvant chemotherapy for invasive bladder cancer: prognostic factors for survival of patients treated with M-VAC with 5-year follow-up.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1994;12(7):1394-401.
-
1994: Davis B E; Herr H W; Fair W R; Bosl G J
The management of patients with nonseminomatous germ cell tumors of the testis with serologic disease only after orchiectomy.
The Journal of urology 1994;152(1):111-3; discussion 114.
-
1994: Bosl G J; Chaganti R S
The use of tumor markers in germ cell malignancies.
Hematology/oncology clinics of North America 1994;8(3):573-87.
-
1994: Motzer R J; Reed E; Perera F; Tang D; Shamkhani H; Poirier M C; Tsai W Y; Parker R J; Bosl G J
Platinum-DNA adducts assayed in leukocytes of patients with germ cell tumors measured by atomic absorbance spectrometry and enzyme-linked immunosorbent assay.
Cancer 1994;73(11):2843-52.
-
1994: Murphy B A; Motzer R J; Mazumdar M; Vlamis V; Nisselbaum J; Bajorin D; Bosl G J
Serum tumor marker decline is an early predictor of treatment outcome in germ cell tumor patients treated with cisplatin and ifosfamide salvage chemotherapy.
Cancer 1994;73(10):2520-6.
-
1994: Bosl G J; Ilson D H; Rodriguez E; Motzer R J; Reuter V E; Chaganti R S
Clinical relevance of the i(12p) marker chromosome in germ cell tumors.
Journal of the National Cancer Institute 1994;86(5):349-55.
-
1994: Bosl G J; Fair W R; Herr H W; Bajorin D F; Dalbagni G; Sarkis A S; Reuter V E; Cordon-Cardo C; Sheinfeld J; Scher H I
Bladder cancer: advances in biology and treatment.
Critical reviews in oncology/hematology 1994;16(1):33-70.
-
1994: Feuer E J; Frey C M; Brawley O W; Nayfield S G; Cunningham J B; Geller N L; Bosl G J; Kramer B S
After a treatment breakthrough: a comparison of trial and population-based data for advanced testicular cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1994;12(2):368-77.
-
1994: Pfister D G; Bajorin D; Motzer R; Scher H; Louison C; Harrison L; Shah J; Strong E; Bosl G
Cisplatin, fluorouracil, and leucovorin. Increased toxicity without improved response in squamous cell head and neck cancer.
Archives of otolaryngology--head & neck surgery 1994;120(1):89-95.
-
1994: Mencel P J; Motzer R J; Mazumdar M; Vlamis V; Bajorin D F; Bosl G J
Advanced seminoma: treatment results, survival, and prognostic factors in 142 patients.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1994;12(1):120-6.
-
1994: Harrison L B; Pfister D G; Kraus D; Armstrong J G; Zelefsky M J; Wiseberg J; Bosl G J; Strong E W; Shah J P
Management of unresectable malignant tumors at the skull base using concomitant chemotherapy and radiotherapy with accelerated fractionation.
Skull base surgery 1994;4(3):127-31.
-
1994: Bajorin D F; Motzer R J; Bosl G J
Germ cell tumors.
Current therapy in endocrinology and metabolism 1994;5():354-9.
-
1994: Bosl G J; Head M D
Serum tumor marker half-life during chemotherapy in patients with germ cell tumors.
The International journal of biological markers 1994;9(1):25-8.
-
1993: Rodriguez E; Houldsworth J; Reuter V E; Meltzer P; Zhang J; Trent J M; Bosl G J; Chaganti R S
Molecular cytogenetic analysis of i(12p)-negative human male germ cell tumors.
Genes, chromosomes & cancer 1993;8(4):230-6.
-
1993: Motzer R J; Mazumdar M; Gulati S C; Bajorin D F; Lyn P; Vlamis V; Bosl G J
Phase II trial of high-dose carboplatin and etoposide with autologous bone marrow transplantation in first-line therapy for patients with poor-risk germ cell tumors.
Journal of the National Cancer Institute 1993;85(22):1828-35.
-
1993: Motzer R J; Gulati S C; Tong W P; Menendez-Botet C; Lyn P; Mazumdar M; Vlamis V; Lin S; Bosl G J
Phase I trial with pharmacokinetic analyses of high-dose carboplatin, etoposide, and cyclophosphamide with autologous bone marrow transplantation in patients with refractory germ cell tumors.
Cancer research 1993;53(16):3730-5.
-
1993: Parker M; Russo P; Reuter V; Bosl G; Keefe D
Intracardiac teratoma 15 years after treatment of a nonseminomatous germ cell tumor.
The Journal of urology 1993;150(2 Pt 1):478-80.
-
1993: Armstrong J; Pfister D; Strong E; Heimann R; Kraus D; Polishook A; Zelefsky M; Bosl G; Shah J; Spiro R
The management of the clinically positive neck as part of a larynx preservation approach.
International journal of radiation oncology, biology, physics 1993;26(5):759-65.
-
1993: Ilson D H; Motzer R J; Rodriguez E; Chaganti R S; Bosl G J
Genetic analysis in the diagnosis of neoplasms of unknown primary tumor site.
Seminars in oncology 1993;20(3):229-37.
-
1993: Chaganti R S; Rodriguez E; Bosl G J
Cytogenetics of male germ-cell tumors.
The Urologic clinics of North America 1993;20(1):55-66.
-
1993: Motzer R J; Bosl G J
Role of adjuvant chemotherapy in patients with stage II nonseminomatous germ-cell tumors.
The Urologic clinics of North America 1993;20(1):111-6.
-
1993: Pfister D G; Bajorin D; Motzer R J; Scher H; Louison C; Harrison L; Shah J; Strong E; Bosl G
A phase II trial of deoxyspergualin in recurrent squamous cell head and neck cancer.
Investigational new drugs 1993;11(1):53-6.
-
1993: Bajorin D F; Motzer R J; Rodriguez E; Murphy B; Bosl G J
Acute nonlymphocytic leukemia in germ cell tumor patients treated with etoposide-containing chemotherapy.
Journal of the National Cancer Institute 1993;85(1):60-2.
-
1993: Bosl G J
Chemotherapy of germ cell tumors: current status and future directions.
European urology 1993;23 Suppl 2():53-6.
-
1993: Bosl G J
Prognostic factors for metastatic testicular germ cell tumours: the Memorial Sloan-Kettering cancer model.
European urology 1993;23(1):182-7.
-
1993: Scher H I; Bajorin D F; Motzer R J; Bosl G J
The evolving role of chemotherapy of germ cell tumors.
Recent results in cancer research. Fortschritte der Krebsforschung. Progrès dans les recherches sur le cancer 1993;126():257-72.
-
1993: Motzer R J; Bosl G J
The current status of salvage chemotherapy for patients with cisplatin-resistant germ cell tumors.
Cancer investigation 1993;11(1):94-6.
-
1992: Motzer R J; Bajorin D F; Vlamis V; Weisen S; Bosl G J
Ifosfamide-based chemotherapy for patients with resistant germ cell tumors: the Memorial Sloan-Kettering Cancer Center experience.
Seminars in oncology 1992;19(6 Suppl 12):8-11.
-
1992: Wood D P; Herr H W; Heller G; Vlamis V; Sogani P C; Motzer R J; Fair W R; Bosl G J
Distribution of retroperitoneal metastases after chemotherapy in patients with nonseminomatous germ cell tumors.
The Journal of urology 1992;148(6):1812-5; discussion 1815-6.
-
1992: Gastl G; Finstad C L; Guarini A; Bosl G; Gilboa E; Bander N H; Gansbacher B
Retroviral vector-mediated lymphokine gene transfer into human renal cancer cells.
Cancer research 1992;52(22):6229-36.
-
1992: Wood D P; Herr H W; Motzer R J; Reuter V; Sogani P C; Morse M J; Bosl G J
Surgical resection of solitary metastases after chemotherapy in patients with nonseminomatous germ cell tumors and elevated serum tumor markers.
Cancer 1992;70(9):2354-7.
-
1992: Murphy B A; Motzer R J; Bosl G J
Phase II study of iproplatin (CHIP) in patients with cisplatin-refractory germ cell tumors; the need for alternative strategies in the investigation of new agents in GCT.
Investigational new drugs 1992;10(4):327-30.
-
1992: Murty V V; Houldsworth J; Baldwin S; Reuter V; Hunziker W; Besmer P; Bosl G; Chaganti R S
Allelic deletions in the long arm of chromosome 12 identify sites of candidate tumor suppressor genes in male germ cell tumors.
Proceedings of the National Academy of Sciences of the United States of America 1992;89(22):11006-10.
-
1992: Motzer R J; Bosl G J
High-dose chemotherapy for resistant germ cell tumors: recent advances and future directions.
Journal of the National Cancer Institute 1992;84(22):1703-9.
-
1992: Bosl G J
The late effects of germ cell tumor chemotherapy: more data are needed.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1992;10(9):1375-6.
-
1992: Ilson D H; Motzer R J; Kradin R L; Vogelzang N J; Bajorin D F; Scher H I; Nanus D; O'Moore P; Marathias K; Bosl G J
A phase II trial of interleukin-2 and interferon alfa-2a in patients with advanced renal cell carcinoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1992;10(7):1124-30.
-
1992: Rodriguez E; Mathew S; Mukherjee A B; Reuter V E; Bosl G J; Chaganti R S
Analysis of chromosome 12 aneuploidy in interphase cells from human male germ cell tumors by fluorescence in situ hybridization.
Genes, chromosomes & cancer 1992;5(1):21-9.
-
1992: Motzer R J; Bajorin D F; Bosl G J
"Poor-risk" germ cell tumors: current progress and future directions.
Seminars in oncology 1992;19(2):206-14.
-
1992: Bajorin D F; Herr H; Motzer R J; Bosl G J
Current perspectives on the role of adjunctive surgery in combined modality treatment for patients with germ cell tumors.
Seminars in oncology 1992;19(2):148-58.
-
1992: Rodriguez E; Mathew S; Reuter V; Ilson D H; Bosl G J; Chaganti R S
Cytogenetic analysis of 124 prospectively ascertained male germ cell tumors.
Cancer research 1992;52(8):2285-91.
-
1992: Kurie J M; Bosl G J; Dmitrovsky E
The genetic and biologic aspects of treatment response and resistance in male germ cell cancer.
Seminars in oncology 1992;19(2):197-205.
-
1992: Pfister D G; Harrison L B; Strong E W; Bosl G J
Current status of larynx preservation with multimodality therapy.
Oncology (Williston Park, N.Y.) 1992;6(3):33-8, 43; discussion 44, 47.
-
1992: Dmitrovsky E; Bosl G J
Active cancer therapy combining 13-cis-retinoic acid with interferon-alpha.
Journal of the National Cancer Institute 1992;84(4):218-9.
-
1991: Seidman A D; Scher H I; Heinemann M H; Bajorin D F; Sternberg C N; Dershaw D D; Silverberg M; Bosl G J
Continuous infusion gallium nitrate for patients with advanced refractory urothelial tract tumors.
Cancer 1991;68(12):2561-5.
-
1991: Ilson D H; Bosl G J; Motzer R; Dmitrovsky E; Chaganti R S
Genetic analysis of germ cell tumors: current progress and future prospects.
Hematology/oncology clinics of North America 1991;5(6):1271-83.
-
1991: Harrison L B; Pfister D G; Fass D E; Armstrong J G; Sessions R B; Shah J P; Spiro R H; Strong E W; Weisen S; Bosl G J
Concomitant chemotherapy-radiation therapy followed by hyperfractionated radiation therapy for advanced unresectable head and neck cancer.
International journal of radiation oncology, biology, physics 1991;21(3):703-8.
-
1991: Mukherjee A B; Murty V V; Rodriguez E; Reuter V E; Bosl G J; Chaganti R S
Detection and analysis of origin of i(12p), a diagnostic marker of human male germ cell tumors, by fluorescence in situ hybridization.
Genes, chromosomes & cancer 1991;3(4):300-7.
-
1991: Toner G C; Geller N L; Lin S Y; Bosl G J
Extragonadal and poor risk nonseminomatous germ cell tumors. Survival and prognostic features.
Cancer 1991;67(8):2049-57.
-
1991: Motzer R J; Rodriguez E; Reuter V E; Samaniego F; Dmitrovsky E; Bajorin D F; Pfister D G; Parsa N Z; Chaganti R S; Bosl G J
Genetic analysis as an aid in diagnosis for patients with midline carcinomas of uncertain histologies.
Journal of the National Cancer Institute 1991;83(5):341-6.
-
1991: Bosl G J; Geller N L; Bajorin D
Serum tumor markers and patient allocation to good-risk and poor-risk clinical trials in patients with germ cell tumors.
Cancer 1991;67(5):1299-304.
-
1991: Motzer R J; Geller N L; Tan C C; Herr H; Morse M; Fair W; Sheinfeld J; Sogani P; Russo P; Bosl G J
Salvage chemotherapy for patients with germ cell tumors. The Memorial Sloan-Kettering Cancer Center experience (1979-1989).
Cancer 1991;67(5):1305-10.
-
1991: Rodriguez E; Reuter V E; Mies C; Bosl G J; Chaganti R S
Abnormalities of 2q: a common genetic link between rhabdomyosarcoma and hepatoblastoma?
Genes, chromosomes & cancer 1991;3(2):122-7.
-
1991: Harrison L B; Pfister D G; Bosl G J
Chemotherapy as part of the initial treatment for nasopharyngeal cancer.
Oncology (Williston Park, N.Y.) 1991;5(2):67-70;discussion 70-1,74,79 passim.
-
1991: Bajorin D F; Geller N L; Weisen S F; Bosl G J
Two-drug therapy in patients with metastatic germ cell tumors.
Cancer 1991;67(1):28-32.
-
1991: Bosl G J; Strong E; Harrison L; Pfister D G
Chemotherapy and the management of locally advanced squamous cell carcinoma of the head and neck: role in larynx preservation.
Important advances in oncology 1991;():191-203.
-
1991: Herr H W; Toner G C; Geller N L; Bosl G J
Patient selection for retroperitoneal lymph node dissection after chemotherapy for nonseminomatous germ cell tumors.
European urology 1991;19(1):1-5.
-
1991: Pfister D G; Bosl G J
BOMM: new solution or old problem?
Cancer investigation 1991;9(5):605-6.
-
1991: Dmitrovsky E; Rodriguez E; Samaniego F; Reuter V E; Miller W H; Geller N L; Bosl G J; Chaganti R S
Analysis of chromosome 12 abnormalities in male germ cell cancers.
Recent results in cancer research. Fortschritte der Krebsforschung. Progrès dans les recherches sur le cancer 1991;123():119-23.
-
1991: Bajorin D F; Geller N L; Bosl G J
Assessment of risk in metastatic testis carcinoma: impact on treatment.
Urologia internationalis 1991;46(3):298-303.
-
1991: Bajorin D F; Bosl G J
Continued refinement in the treatment of germ cell tumour patients.
European journal of cancer (Oxford, England : 1990) 1991;27(6):677-8.
-
1990: Murty V V; Dmitrovsky E; Bosl G J; Chaganti R S
Nonrandom chromosome abnormalities in testicular and ovarian germ cell tumor cell lines.
Cancer genetics and cytogenetics 1990;50(1):67-73.
-
1990: Toner G C; Bosl G J
Sarcoidosis, "Sarcoid-like lymphadenopathy," and testicular germ cell tumors.
The American journal of medicine 1990;89(5):651-6.
-
1990: Motzer R; Scher H; Bajorin D; Sternberg C; Bosl G J
Phase II trial of Didemnin B in patients with advanced renal cell carcinoma.
Investigational new drugs 1990;8(4):391-2.
-
1990: Toner G C; Geller N L; Tan C; Nisselbaum J; Bosl G J
Serum tumor marker half-life during chemotherapy allows early prediction of complete response and survival in nonseminomatous germ cell tumors.
Cancer research 1990;50(18):5904-10.
-
1990: Motzer R J; Geller N L; Bosl G J
The effect of a 7-day delay in chemotherapy cycles on complete response and event-free survival in good-risk disseminated germ cell tumor patients.
Cancer 1990;66(5):857-61.
-
1990: Cooper K; Bajorin D; Shapiro W; Krol G; Sze G; Bosl G J
Decompression of epidural metastases from germ cell tumors with chemotherapy.
Journal of neuro-oncology 1990;8(3):275-80.
-
1990: Panicek D M; Toner G C; Heelan R T; Bosl G J
Nonseminomatous germ cell tumors: enlarging masses despite chemotherapy.
Radiology 1990;175(2):499-502.
-
1990: Dmitrovsky E; Murty V V; Moy D; Miller W H; Nanus D; Albino A P; Samaniego F; Bosl G; Chaganti R S
Isochromosome 12p in non-seminoma cell lines: karyologic amplification of c-ki-ras2 without point-mutational activation.
Oncogene 1990;5(4):543-8.
-
1990: Ladanyi M; Samaniego F; Reuter V E; Motzer R J; Jhanwar S C; Bosl G J; Chaganti R S
Cytogenetic and immunohistochemical evidence for the germ cell origin of a subset of acute leukemias associated with mediastinal germ cell tumors.
Journal of the National Cancer Institute 1990;82(3):221-7.
-
1990: Ganguly S; Murty V V; Samaniego F; Reuter V E; Bosl G J; Chaganti R S
Detection of preferential NRAS mutations in human male germ cell tumors by the polymerase chain reaction.
Genes, chromosomes & cancer 1990;1(3):228-32.
-
1990: Scher H; Herr H; Sternberg C; Fair W; Bosl G; Morse M; Sogani P; Watson R; Darshaw D; Reuter V
M-VAC (methotrexate, vinblastine, adriamycin and cisplatin) and bladder preservation.
Progress in clinical and biological research 1990;353():179-86.
-
1990: Motzer R J; Niedzwiecki D; Isaacs M; Menendez-Botet C; Tong W P; Flombaum C; Scher H I; Bosl G J
Carboplatin-based chemotherapy with pharmacokinetic analysis for patients with hemodialysis-dependent renal insufficiency.
Cancer chemotherapy and pharmacology 1990;27(3):234-8.
-
1990: Stoter G; Bosl G J; Droz J P; Fossa S D; Freedman L S; Geller N L; Horwich A; Jones W G; Kaye S B; Mead G M
Prognostic factors in metastatic germ cell tumors.
Progress in clinical and biological research 1990;357():313-9.
-
1990: Iannotti N I; Bosl G J
A review of the management of germ cell tumors: evolution of a curative treatment program.
Cancer investigation 1990;8(2):173-9.
-
1990: Dmitrovsky E; Bosl G J; Chaganti R S
Clinical and genetic features of human germ cell cancer.
Cancer surveys 1990;9(2):369-86.
-
1989: Bosl G J; Dmitrovsky E; Reuter V E; Samaniego F; Rodriguez E; Geller N L; Chaganti R S
Isochromosome of the short arm of chromosome 12: clinically useful markers for male germ cell tumors.
Journal of the National Cancer Institute 1989;81(24):1874-8.
-
1989: Scher H; Herr H; Sternberg C; Fair W; Bosl G; Morse M; Sogani P; Watson R; Dershaw D; Reuter V
Neo-adjuvant chemotherapy for invasive bladder cancer. Experience with the M-VAC regimen.
British journal of urology 1989;64(3):250-6.
-
1989: Chaganti R S; Ladanyi M; Samaniego F; Offit K; Reuter V E; Jhanwar S C; Bosl G J
Leukemic differentiation of a mediastinal germ cell tumor.
Genes, chromosomes & cancer 1989;1(1):83-7.
-
1989: Schwarzman M I; Russo P; Bosl G J; Whitmore W F
Hormone-secreting metastatic interstitial cell tumor of the testis.
The Journal of urology 1989;141(3):620-2.
-
1989: Geller N L; Bosl G J; Chan E Y
Prognostic factors for relapse after complete response in patients with metastatic germ cell tumors.
Cancer 1989;63(3):440-5.
-
1989: Nanus D M; Bosl G J
Systemic chemotherapy in the management of bladder cancer.
Cancer treatment and research 1989;46():143-58.
-
1988: Motzer R J; Reuter V E; Cordon-Cardo C; Bosl G J
Blood group-related antigens in human germ cell tumors.
Cancer research 1988;48(18):5342-7.
-
1988: Bosl G J; Geller N L; Bajorin D
Identification and management of poor risk patients with germ cell tumors: the Memorial Sloan-Kettering Cancer Center experience.
Seminars in oncology 1988;15(4):339-44.
-
1988: Bosl G J; Geller N L; Bajorin D; Leitner S P; Yagoda A; Golbey R B; Scher H; Vogelzang N J; Auman J; Carey R
A randomized trial of etoposide + cisplatin versus vinblastine + bleomycin + cisplatin + cyclophosphamide + dactinomycin in patients with good-prognosis germ cell tumors.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1988;6(8):1231-8.
-
1988: Bosl G J; Geller N L; Chan E Y
Stage migration and the increasing proportion of complete responders in patients with advanced germ cell tumors.
Cancer research 1988;48(12):3524-7.
-
1988: Bajorin D; Katz A; Chan E; Geller N; Vogelzang N; Bosl G J
Comparison of criteria for assigning germ cell tumor patients to "good risk" and "poor risk" studies.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1988;6(5):786-92.
-
1988: Motzer R J; Bosl G J; Geller N L; Penenberg D; Yagoda A; Golbey R; Whitmore W F; Fair W R; Sogani P; Herr H
Advanced seminoma: the role of chemotherapy and adjunctive surgery.
Annals of internal medicine 1988;108(4):513-8.
-
1988: Scher H I; Yagoda A; Herr H W; Sternberg C N; Bosl G; Morse M J; Sogani P C; Watson R C; Dershaw D D; Reuter V
Neoadjuvant M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) effect on the primary bladder lesion.
The Journal of urology 1988;139(3):470-4.
-
1988: Scher H I; Shank B; Chapman R; Geller N; Pinsky C; Gralla R; Kelsen D; Bosl G; Golbey R; Petroni G
Randomized trial of combined modality therapy with and without thymosin fraction V in the treatment of small cell lung cancer.
Cancer research 1988;48(6):1663-70.
-
1988: Vikram B; Bosl G J; Pfister D; Assad W; Strong E W; Spiro R H; Sessions R B; Gerold F P; Shah J P
New strategies for avoiding total laryngectomy in patients with head and neck cancer.
NCI monographs : a publication of the National Cancer Institute 1988;(6):361-4.
-
1988: Sternberg C N; Yagoda A; Scher H I; Whitmore W F; Herr H W; Morse M J; Sogani P C; Bosl G; Watson R C; Hollander P S
Neo-adjuvant M-VAC chemotherapy trials in transitional cell carcinoma: perspectives for first line chemotherapy.
Progress in clinical and biological research 1988;260():551-5.
-
1988: Sternberg C N; Bosl G J
Advances in testicular cancer--role of chemotherapy.
Progress in clinical and biological research 1988;277():79-84.
-
1987: Bajorin D; Bosl G J; Fein R
Phase I trial of escalating doses of cisplatin in hypertonic saline.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1987;5(10):1589-93.
-
1987: Haines I; Bosl G; Pfister D; Spiro R; Gerold F; Sessions R; Shah J; Strong E; Vikram B; Harrison L
Very-high-dose cisplatin with bleomycin infusion as initial treatment of advanced head and neck cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1987;5(10):1594-600.
-
1987: Motzer R J; Bosl G J
Hemorrhage: a complication of metastatic testicular choriocarcinoma.
Urology 1987;30(2):119-22.
-
1987: Leitner S P; Bosl G J; Pelus L M
Abnormal colony formation and prostaglandin E responsiveness of myeloid progenitor cells in patients cured of germ cell neoplasms after combination chemotherapy.
Cancer 1987;60(3):312-7.
-
1987: Motzer R; Bosl G; Heelan R; Fair W; Whitmore W; Sogani P; Herr H; Morse M
Residual mass: an indication for further therapy in patients with advanced seminoma following systemic chemotherapy.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1987;5(7):1064-70.
-
1987: Herr H W; Bosl G
Residual mass after chemotherapy for seminoma: changing concepts of management.
The Journal of urology 1987;137(6):1234-5.
-
1987: Motzer R J; Bosl G J
Chemotherapy for germ cell tumors.
The Urologic clinics of North America 1987;14(2):389-98.
-
1987: White D A; Schwartzberg L S; Kris M G; Bosl G J
Acute chest pain syndrome during bleomycin infusions.
Cancer 1987;59(9):1582-5.
-
1987: Bosl G J; Geller N L; Vogelzang N J; Carey R; Auman J; Whitmore W F; Herr H; Morse M; Sogani P; Chan E
Alternating cycles of etoposide plus cisplatin and VAB-6 in the treatment of poor-risk patients with germ cell tumors.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1987;5(3):436-40.
-
1987: Bosl G J; Bajorin D; Geller N L
An analysis of poor risk assignment in patients with germ cell tumours.
International journal of andrology 1987;10(1):285-9.
-
1987: Motzer R J; Bosl G J; Tauer K; Golbey R
Phase II trial of carboplatin in patients with advanced germ cell tumors refractory to cisplatin.
Cancer treatment reports 1987;71(2):197-8.
-
1987: Bosl G J; Bajorunas D
Pituitary and testicular hormonal function after treatment for germ cell tumours.
International journal of andrology 1987;10(1):381-4.
-
1987: Bosl G J; Leitner S P; Atlas S A; Sealey J E; Preibisz J J; Scheiner E
Altered renin and aldosterone excretion in patients treated for metastatic germ cell tumours.
International journal of andrology 1987;10(1):353-7.
-
1987: Casper E S; Guidera C A; Bosl G J; Hakes T B; Kaufman R J; Shurgot B; Kinne D W
Combined modality treatment of locally advanced breast cancer: adjuvant combination chemotherapy with and without doxorubicin.
Breast cancer research and treatment 1987;9(1):39-44.
-
1986: Bajorin D F; Bosl G J; Alcock N W; Niedzwiecki D; Gallina E; Shurgot B
Pharmacokinetics of cis-diamminedichloroplatinum(II) after administration in hypertonic saline.
Cancer research 1986;46(11):5969-72.
-
1986: Bosl G J; Leitner S P; Atlas S A; Sealey J E; Preibisz J J; Scheiner E
Increased plasma renin and aldosterone in patients treated with cisplatin-based chemotherapy for metastatic germ-cell tumors.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1986;4(11):1684-9.
-
1986: Nisselbaum J S; Bosl G; Schwartz M K
Argument in favor of using mass units to calibrate and report concentrations of human choriogonadotropin.
Clinical chemistry 1986;32(10):1998-2000.
-
1986: Leitner S P; Bosl G J; Bajorunas D
Gonadal dysfunction in patients treated for metastatic germ-cell tumors.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1986;4(10):1500-5.
-
1986: Bosl G J; Gluckman R; Geller N L; Golbey R B; Whitmore W F; Herr H; Sogani P; Morse M; Martini N; Bains M
VAB-6: an effective chemotherapy regimen for patients with germ-cell tumors.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1986;4(10):1493-9.
-
1986: Leitner S P; Bosl G J; Strong E W; Gerold F P; Spiro R H; Shah J P; Sessions R B; Vikram B
A pilot study of cisplatin-vinblastine as the initial treatment of advanced head and neck cancer.
Cancer 1986;58(5):1014-7.
-
1986: Tiffany P; Morse M J; Bosl G; Vaughan E D; Sogani P C; Herr H W; Whitmore W F
Sequential excision of residual thoracic and retroperitoneal masses after chemotherapy for stage III germ cell tumors.
Cancer 1986;57(5):978-83.
-
1985: Tyson L B; Gralla R J; Clark R A; Kris M G; Bordin L A; Bosl G J
Phase 1 trial of levonantradol in chemotherapy-induced emesis.
American journal of clinical oncology 1985;8(6):528-32.
-
1985: Ahmed T; Bosl G J; Hajdu S I
Teratoma with malignant transformation in germ cell tumors in men.
Cancer 1985;56(4):860-3.
-
1985: Israel A; Bosl G J; Golbey R B; Whitmore W; Martini N
The results of chemotherapy for extragonadal germ-cell tumors in the cisplatin era: the Memorial Sloan-Kettering Cancer Center experience (1975 to 1982).
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1985;3(8):1073-8.
-
1985: Chun H; Bosl G J
Phase II trial of mitoguazone in patients with refractory germ cell tumors.
Cancer treatment reports 1985;69(4):461-2.
-
1985: Chun H; Bosl G J; Golbey R B
Phase II trial of 1,2-diaminocyclohexane-(4-carboxyphthalato) platinum(II) in patients with refractory germ cell tumors.
Cancer treatment reports 1985;69(4):459-60.
-
1985: Bosl G J; Yagoda A; Golbey R B; Whitmore W; Herr H; Sogani P; Morse M; Vogelzang N; MacDonald G
Role of etoposide-based chemotherapy in the treatment of patients with refractory or relapsing germ cell tumors.
The American journal of medicine 1985;78(3):423-8.
-
1985: Stanton G F; Bosl G J; Whitmore W F; Herr H; Sogani P; Morse M; Golbey R B
VAB-6 as initial treatment of patients with advanced seminoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1985;3(3):336-9.
-
1985: Kris M G; Gralla R J; Tyson L B; Clark R A; Kelsen D P; Reilly L K; Groshen S; Bosl G J; Kalman L A
Improved control of cisplatin-induced emesis with high-dose metoclopramide and with combinations of metoclopramide, dexamethasone, and diphenhydramine. Results of consecutive trials in 255 patients.
Cancer 1985;55(3):527-34.
-
1985: Magee M J; Howard J; Bosl G J; Wittes R E
Phase II trial of 4'-epi-doxorubicin in advanced carcinoma of head and neck origin.
Cancer treatment reports 1985;69(1):125-6.
-
1984: Bosl G J
Adjuvant surgery in the management of patients with germ cell tumors.
The Annals of thoracic surgery 1984;38(5):432.
-
1984: Thongprasert S; Bosl G J; Geller N L; Wittes R E
Phase II trial of mitoguazone in patients with advanced head and neck cancer.
Cancer treatment reports 1984;68(10):1301-2.
-
1984: Gold E J; Bosl G J; Itri L M
Phase II trial of 13-cis-retinoic acid in patients with advanced nonseminomatous germ cell tumors.
Cancer treatment reports 1984;68(10):1287-8.
-
1984: Bosl G J; Yagoda A; Whitmore W F; Sogani P; Herr H; Vugrin D; Dukeman M; Golbey R
VP-16-213 and cisplatin in the treatment of patients with refractory germ cell tumors.
American journal of clinical oncology 1984;7(4):327-30.
-
1984: Jain K K; Bosl G J; Bains M S; Whitmore W F; Golbey R B
The treatment of extragonadal seminoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1984;2(7):820-7.
-
1984: Nisselbaum J S; Bosl G J; Golbey R B; Schwartz D C; Schwartz M K
Changes in serum alpha-fetoprotein and chorionic gonadotropin in response to cancer therapy.
Annals of clinical and laboratory science 1984;14(3):179-88.
-
1984: Sogani P C; Whitmore W F; Herr H W; Bosl G J; Golbey R B; Watson R C; DeCosse J J
Orchiectomy alone in the treatment of clinical stage I nonseminomatous germ cell tumor of the testis.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1984;2(4):267-70.
-
1983: Bosl G J; Geller N L; Cirrincione C; Vogelzang N J; Kennedy B J; Whitmore W F; Vugrin D; Scher H; Nisselbaum J; Golbey R B
Multivariate analysis of prognostic variables in patients with metastatic testicular cancer.
Cancer research 1983;43(7):3403-7.
-
1983: Bosl G J; Geller N L; Cirrincione C; Nisselbaum J; Vugrin D; Whitmore W F; Golbey R B
Serum tumor markers in patients with metastatic germ cell tumors of the testis. A 10-year experience.
The American journal of medicine 1983;75(1):29-35.
-
1983: Scher H; Bosl G; Geller N; Cirrincione C; Whitmore W; Golbey R
Impact of symptomatic interval on prognosis of patients with stage III testicular cancer.
Urology 1983;21(6):559-61.
-
1983: Bosl G J; Geller N; Cirrincione C; Hajdu S I; Whitmore W; Nisselbaum J; Vugrin D; Golbey R B
Interrelationships of histopathology and other clinical variables in patients with germ cell tumors of the testis.
Cancer 1983;51(11):2121-5.
-
1983: Bosl G J
Adjuvant chemotherapy in the management of stage III and IV tumors of the head and neck.
CA: a cancer journal for clinicians 1983;33(3):139-44.
-
1982: Raghavan D; Vogelzang N J; Bosl G J; Nochomovitz L E; Rosai J; Lange P H; Fraley E E; Goldman A; Torkelson J; Kennedy B J
Tumor classification and size in germ-cell testicular cancer: influence on the occurrence of metastases.
Cancer 1982;50(8):1591-5.
-
1981: Bosl G J; Vogelzang N J; Goldman A; Fraley E E; Lange P H; Levitt S H; Kennedy B J
Impact of delay in diagnosis on clinical stage of testicular cancer.
Lancet 1981;2(8253):970-3.
-
1981: Vogelzang N J; Bosl G J; Johnson K; Kennedy B J
Raynaud's phenomenon: a common toxicity after combination chemotherapy for testicular cancer.
Annals of internal medicine 1981;95(3):288-92.
-
1981: Bosl G J; Lange P H; Nochomovitz L E; Goldmann A; Fraley E E; Rosai J; Johnson K; Kennedy B J
Tumor markers in advanced nonseminomatous testicular cancer.
Cancer 1981;47(3):572-6.
-
1981: Bosl G J; Lange P H; Fraley E E; Goldman A; Nochomovitz L E; Rosai J; Waldmann T A; Johnson K; Kennedy B J
Human chorionic gonadotropin and alphafetoprotein in the staging of nonseminomatous testicular cancer.
Cancer 1981;47(2):328-32.
-
1980: Peterson B A; Bloomfield C D; Bosl G J; Gibbs G; Malloy M
Intensive five-drug combination chemotherapy for adult acute non-lymphocytic leukemia.
Cancer 1980;46(4):663-8.
-
1980: Bosl G J; Lange P H; Fraley E E; Nochomovitz L E; Rosai J; Vogelzang N J; Johnson K; Goldman A; Kennedy B J
Vinblastine, bleomycin and cis-diamminedichloroplatinum in the treatment of advanced testicular carcinoma. Possible importance of longer induction and shorter maintenance schedules.
The American journal of medicine 1980;68(4):492-6.
-
1980: Ewing G E; Bosl G J; Peterson P K
Sporothrix schenckii meningitis in a farmer with Hodgkin's disease.
The American journal of medicine 1980;68(3):455-7.
-
1980: Bosl G J; Kwong R; Lange P H; Fraley E E; Kennedy B J
Vinblastine, intermittent bleomycin, and single-dose cis-dichlorodiammineplatinum(II) in the management of stge III testicular cancer.
Cancer treatment reports 1980;64(2-3):331-4.
-
1980: Bosl G J; Yagoda A; Camara-Lopes L H
Malignant carcinoid of the gallbladder: third reported case and review of the literature.
Journal of surgical oncology 1980;13(3):215-22.
-
1979: Bosl G J; Edson J R
Intravascular coagulation.
Minnesota medicine 1979;62(7):544-6.
-
1979: Bosl G J
Chorionic gonadotrophin and alpha-fetoprotein markers for testicular cancer.
Minnesota medicine 1979;62(7):507-8.
Sign-in to see more